Drug Search Results
More Filters [+]

Rolofylline

Alternative Names: rolofylline
Latest Update: 2023-05-25
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: ADORA1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rolofylline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Heart Failure

Phase 2: Heart Failure|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PROTECT-1

P3

Completed

Heart Failure

2009-07-01

PROTECT-2

P3

Completed

Heart Failure

2009-07-01

2008-002209-38

P2

Terminated

Kidney Diseases|Heart Failure

2009-03-06

MK7418-503

P2

Completed

Heart Failure

2009-03-01

Recent News Events